Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib

doi:10.1158/1078-0432.CCR-17-1875

	Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
	Liu, Shengwu 1; Li, Shuai 2,3; Hai, Josephine 1; Wang, Xiaoen 1; Chen, Ting 3; Quinn, Max M.1; Gao, Peng 1; Zhang, Yanxi 1; Ji, Hongbin4,5 ; Cross, Darren A. E.6; Wong, Kwok-Kin 3
	2018-06
发表期刊	CLINICAL CANCER RESEARCH
ISSN	1078-0432
卷号	24 期号:11 页码:2594-2604
发表状态	已发表
DOI	10.1158/1078-0432.CCR-17-1875
摘要	Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations, have been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas. HER2 amplification is also an important mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (TKI). However, due to limited preclinical studies and clinical trials, currently there is still no available standard of care for lung cancer patients with HER2 aberrations. To fulfill the clinical need for targeting HER2 in patients with non-small cell lung cancer (NSCLC), we performed a comprehensive preclinical study to evaluate the efficacy of a third-generation TKI, osimertinib (AZD9291).
收录类别	SCI ; SCIE
语种	英语
资助项目	National Cancer Institute[R01 CA195740] ; National Cancer Institute[CA205150] ; National Cancer Institute[CA166480] ; National Cancer Institute[CA140594] ; National Cancer Institute[P01 CA154303] ; National Cancer Institute[U01 CA213333]
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000433971400015
出版者	AMER ASSOC CANCER RESEARCH
WOS关键词	RECEPTOR TYROSINE KINASE ; PHASE-II TRIAL ; BROMODOMAIN INHIBITION ; ACQUIRED-RESISTANCE ; DOMAIN MUTATIONS ; EGFR ; MUTANT ; NSCLC ; COMBINATION ; AZD9291
原始文献类型	Article
引用统计
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/23093
专题	生命科学与技术学院_特聘教授组_季红斌组
通讯作者	Wong, Kwok-Kin
作者单位	1.Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA 2.Tongji Univ, Sch Med, Shanghai Tongji Hosp, Dept Pathol, Shanghai, Peoples R China 3.NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA 4.Chinese Acad Sci, Innovat Ctr Cell Signaling Network, CAS Ctr Excellence Mol Cell Sci,Inst Biochem & Ce, Shanghai Inst Biol Sci,State Key Lab Cell Biol, Shanghai, Peoples R China 5.Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China 6.AstraZeneca Oncol Innovat Med, Alderley Pk, Macclesfield, Cheshire, England
推荐引用方式 GB/T 7714	Liu, Shengwu,Li, Shuai,Hai, Josephine,et al. Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib[J]. CLINICAL CANCER RESEARCH,2018,24(11):2594-2604.
APA	Liu, Shengwu.,Li, Shuai.,Hai, Josephine.,Wang, Xiaoen.,Chen, Ting.,...&Wong, Kwok-Kin.(2018).Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.CLINICAL CANCER RESEARCH,24(11),2594-2604.
MLA	Liu, Shengwu,et al."Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib".CLINICAL CANCER RESEARCH 24.11(2018):2594-2604.